US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist
  • 3.170
  • -0.010-0.31%
Close Dec 24 13:00 ET
  • 3.160
  • -0.010-0.32%
Post 13:27 ET
318.03MMarket Cap-1.20P/E (TTM)

Acelyrin Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Acelyrin Q3 2024 Earnings Date

Currency：USDNov 13, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
EPS
-0.81
-0.49
+0.32
Beat Est.
+6.90%
+43.68%
+39.50%
Net Income
--
-48.55M
--
+42.16%
Analyst Rating
Buy

Dec 19, 2024

Acelyrin Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Acelyrin Earnings Reports

  • Acelyrin | 10-Q: Q3 2024 Earnings Report

    Nov 14 05:10

  • Acelyrin | 8-K: ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

    Nov 14 05:09

  • Acelyrin | 10-Q: Q2 2024 Earnings Report

    Aug 14 04:24

  • Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

    Aug 14 04:18

    • Read more

    Analysis

    Analyst Rating

    Updated: Dec 19, 2024

    Buy

    • Buy

      60.00%

    • Hold

      40.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data